Clinical Trial: Hepatitis B Virus Genotype and a Combination of End‐of‐Treatment Biomarkers Predict Severe Flares After Nucleos(t)ide Analogue Cessation
Alimentary Pharmacology & Therapeutics · 2026-02 · 63 (3) · 352-361
DOI: 10.1111/apt.70465 ↗At a glance
Klinische Studie in Alimentary Pharmacology & Therapeutics, published online on 2025-11-19. Written by Arno Furquim d'Almeida and 29 co-authors. Institution: Viral Hepatitis Research Group, Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Antwerp, Belgium. Major MEDLINE topics: Antiviral Agents, Hepatitis B virus, Hepatitis B, Chronic, Nucleosides. Cited 6 times so far (Crossref); 36 references. Funded by: Fonds Wetenschappelijk Onderzoek.
Abstract (original language)
Background
Nucleos(t)ide analogue (NUC) cessation can induce a functional cure in chronic hepatitis B virus (HBV) infections, but severe post‐cessation virologic relapses (SVRel) and severe biochemical flares (SBF) frequently occur.
Aims
To identify predictive biomarkers for patients at highest risk for SVRel and SBF.
Methods
In the multicentre prospective COIN‐B trial, start‐of‐treatment HBeAg‐negative, long‐term virologically suppressed patients without advanced fibrosis are followed up for 72 weeks after NUC cessation. We performed a predefined exploratory analysis of the associations between HBV genotype, or end‐of‐treatment (EOT) biomarkers (HBcrAg, HBV RNA, HBsAg, and anti‐HBc IgG) and SVRel (HBV DNA > 5 log IU/mL) or SBF (ALT > 10× ULN) within 48 weeks post‐cessation.
Results
Of 91 recruited patients, 85 completed 48 weeks of follow‐up. SVRel and SBF occurred in 36 (42.4%) and 21 (24.7%) patients, respectively. Genotypes C, D, and E were associated with higher relapse and flare rates, whereas none of the 18 genotype A patients developed SBF. In multivariate analysis, SVRel was independently associated with detectable HBcrAg (aOR 3.93, p = 0.01), and SBF with non‐A genotype (aOR 19.03, p = 0.018), detectable HBV RNA (aOR 7.84, p = 0.005), and lower anti‐HBc IgG levels (aOR 0.31, p = 0.016). A risk stratification tool, the COBRA score, was developed incorporating HBcrAg, HBV RNA, and anti‐HBc IgG. A score ≥ 2 identified patients at increased risk, with 80.0% sensitivity and 90.7% NPV for SBF.
Conclusions
HBV genotype and EOT biomarkers, including HBcrAg, HBV RNA, and anti‐HBc IgG predict SVRel and SBF following NUC cessation. The COBRA score enables pragmatic, individualised risk stratification. Trial Registration ClinicalTrials.gov identifier: NCT04779970, EudraCT: 2021‐001003‐32
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Viral Hepatitis Research Group, Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Antwerp, Belgium.
- Department of Gastroenterology and Hepatology, Antwerp University Hospital, Antwerp, Belgium.
- Department of Gastroenterology, Ziekenhuis aan de Stroom, Antwerp, Belgium.
- Department of Hepato-Gastroenterology, CHU Saint-Pierre, Brussels, Belgium.
- Department of Gastroenterology, Ziekenhuis Oost-Limburg, Genk, Belgium.
- Department of Gastroenterology, CHU Brugmann, Brussels, Belgium.
ORCID profiles: Arno Furquim d'Almeida, Thomas Vanwolleghem
Funding
- Fonds Wetenschappelijk Onderzoek
Cite
APA
Furquim d'Almeida, A., Vanderlinden, A., Bourgeois, S., Mulkay, J. P., Sersté, T., Struyve, M., Deressa, B., Sprengers, D., de Vos, M., Callens, J., Shihao, B., Reynaert, H., Deltenre, P., Janssens, F., Negrin-Dastis, S., Stärkel, P., Orlent, H., Van Roey, G., Verhelst, X., …, & Vanwolleghem, T. (2026). Clinical Trial: Hepatitis B Virus Genotype and a Combination of End‐of‐Treatment Biomarkers Predict Severe Flares After Nucleos(t)ide Analogue Cessation. Alimentary Pharmacology & Therapeutics, 63(3), 352-361. https://doi.org/10.1111/apt.70465
Vancouver
Furquim d'Almeida A, Vanderlinden A, Bourgeois S, Mulkay JP, Sersté T, Struyve M, et al. Clinical Trial: Hepatitis B Virus Genotype and a Combination of End‐of‐Treatment Biomarkers Predict Severe Flares After Nucleos(t)ide Analogue Cessation. Alimentary Pharmacology & Therapeutics. 2026;63(3):352-361. doi:10.1111/apt.70465
BibTeX
@article{FurquimdAlmeida2026,
author = {Furquim d'Almeida, Arno and Vanderlinden, Axelle and Bourgeois, Stefan and Mulkay, Jean-Pierre and Sersté, Thomas and Struyve, Mathieu and Deressa, Baro and Sprengers, Dirk and de Vos, Marie and Callens, Jos and Shihao, Bao and Reynaert, Hendrik and Deltenre, Pierre and Janssens, Filip and Negrin-Dastis, Sergio and Stärkel, Peter and Orlent, Hans and Van Roey, Guy and Verhelst, Xavier and Moreno, Christophe and Delwaide, Jean and Van Steenkiste, Christophe and Verlinden, Wim and Colle, Isabelle and Plissonnier, Marie-Laure and Mukadi, Benoît Kabamba and Testoni, Barbara and Zoulim, Fabien and Matheeussen, Veerle and Vanwolleghem, Thomas},
title = {Clinical Trial: Hepatitis B Virus Genotype and a Combination of End‐of‐Treatment Biomarkers Predict Severe Flares After Nucleos(t)ide Analogue Cessation},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
volume = {63},
number = {3},
pages = {352--361},
doi = {10.1111/apt.70465}
}
EUVIMED